Developing the tools to fight drug-resistant bacteria

pREVention and management tools for rEducing antibiotic Resistance in high prevalence SEttings

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN12956554

Enrollment

Registered

2021-11-11

Start date

2022-03-01

Completion date

Unknown

Last updated

2026-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Antimicrobial resistance Infections and Infestations

Interventions

Three bundled programmes will be sequentially implemented after a minimum 6-month baseline monitoring period - microbiology and diagnostic stewardship (MDS), infection prevention and control (IPC), an

4. Molecular characterization of blood cultures and samples from lower respiratory tracts (HAP) to inform ABS 5. Rapid tests if molecular tests are unavailable (e.g. CARBA-5 or beta-LACTA) 6. Molecu

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All adult inpatients in participating centers in intensive care, internal medicine, haematology-oncology, and surgery (including transplant units)

Exclusion criteria

Exclusion criteria: 1. Patients in settings other than mentioned above 2. Children, infants, or neonates

Design outcomes

Primary

Measure	Time frame
Incidence density (N/1000 patient-days) of healthcare-acquired infections due to carbapenem-resistant Acinetobacter baumannii (CRAB), carbapenem-resistant enterobacteriales (CRE), and carbapenem-resistant Pseudomonas aeruginosa (CRPA), measured by prospective surveillance using laboratory and chart information every 3 months starting at baseline and continuing until the end of the study	—

Secondary

Measure	Time frame
1. Quarterly proportions of HAI due to CRE, CRPA, and CRAB measured by prospective surveillance using laboratory and chart information every 3 months starting at baseline and continuing until the end of the study 2. Incidence density (N/1000 patient-days) of healthcare-associated bloodstream infection of any type measured using existing surveillance in hospitals every 3 months starting at baseline and continuing until the end of the study 3. Incidence density (N/1000 patient-days) and quarterly proportions of HAI due to other clinically important multidrug-resistant organisms (such as ESBL-producing Klebsiella pneumonia, methicillin-resistant Stapyhlococcus aureus, and vancomycin-resistant enterococci) measured using existing surveillance in hospitals every 3 months starting at baseline and continuing until the end of the study 4. Incidence density (N/10,000 patient-days) of Clostridium difficile infection (as a proxy for the consumption of broad-spectrum antibiotics) measured using existing surveillance in hospitals every 3 months starting at baseline and continuing until the end of the study 5. Performed blood culture sets per 1000 patient-days measured using laboratory data every 3 months starting at baseline and continuing until the end of the study 6. Performed stool tests for Clostridioides difficile per 1000 patient-days measured using laboratory data every 3 months starting at baseline and continuing until the end of the study 7. Consumption of alcohol-based handrub solution per 1000 patient-days measured using administrative data every 3 months starting at baseline and continuing until the end of the study 8. Antimicrobial consumption in daily-defined doses over the last 3 months measured using administrative data every 3 months starting at baseline and continuing until the end of the study 9. Prevalence of CRE colonisation measured via rectal swabs at the beginning of the infection prevention and control programme (IPC), at the end of the IPC programme, an	—

Measure

Time frame

1. Quarterly proportions of HAI due to CRE, CRPA, and CRAB measured by prospective surveillance using laboratory and chart information every 3 months starting at baseline and continuing until the end of the study 2. Incidence density (N/1000 patient-days) of healthcare-associated bloodstream infection of any type measured using existing surveillance in hospitals every 3 months starting at baseline and continuing until the end of the study 3. Incidence density (N/1000 patient-days) and quarterly proportions of HAI due to other clinically important multidrug-resistant organisms (such as ESBL-producing Klebsiella pneumonia, methicillin-resistant Stapyhlococcus aureus, and vancomycin-resistant enterococci) measured using existing surveillance in hospitals every 3 months starting at baseline and continuing until the end of the study 4. Incidence density (N/10,000 patient-days) of Clostridium difficile infection (as a proxy for the consumption of broad-spectrum antibiotics) measured using existing surveillance in hospitals every 3 months starting at baseline and continuing until the end of the study 5. Performed blood culture sets per 1000 patient-days measured using laboratory data every 3 months starting at baseline and continuing until the end of the study 6. Performed stool tests for Clostridioides difficile per 1000 patient-days measured using laboratory data every 3 months starting at baseline and continuing until the end of the study 7. Consumption of alcohol-based handrub solution per 1000 patient-days measured using administrative data every 3 months starting at baseline and continuing until the end of the study 8. Antimicrobial consumption in daily-defined doses over the last 3 months measured using administrative data every 3 months starting at baseline and continuing until the end of the study 9. Prevalence of CRE colonisation measured via rectal swabs at the beginning of the infection prevention and control programme (IPC), at the end of the IPC programme, an

—

Countries

Greece, Italy, Romania, Spain

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 20, 2026